Aktuellt
SENASTE
Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s recent share issue. Overall, we are encouraged to see that the company has succeeded in raising capital to satisfy its funding needs. We argue that this capital raise has placed the company in a position where it can increase shareholder value through achieving crucial upcoming milestones. Having adjusted for the share issue, we revise our valuation with an updated base case.
LÄS MER
